Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS safety_alert · 2013-04-22

Clinical Trial Update: Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures

View source ↗

Summary

Post-authorization safety study update assessing the safety of Vimpat (lacosamide) as add-on therapy in patients with partial-onset seizures.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Vimpat (lacosamide)

Snippet

Sponsor: UCB Pharma | Conditions: Epilepsies, Partial | Status: COMPLETED | Results posted: 2013-04-22